ReviewTaiwan journal of ophthalmology
The prevalence, progression, and visual loss associated with myopic macular degeneration in Asia.
Review in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence, Associations, and Visual Impact of Myopic Macular Degeneration in a Multi-ethnic Older Population in Singapore: The PIONEER Study.Ophthalmology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review examines the epidemiology, natural history, and visual outcomes of myopic macular degeneration (MMD) in Asia. MMD is irreversible, may affect both eyes, and may occur during a person's productive years, making it a significant public health concern. Population-based studies report a wide variation in MMD prevalence, ranging from 0.24% in rural India to 4.5% in mainland China. MMD is etiologically heterogeneous, with its prevalence associated with a more negative spherical equivalent (SE), longer axial length (AL), older age, and a lower education level. The development of MMD is likely nonlinear, with the prevalence of MMD increasing markedly once specific thresholds in age (60-70 years), SE (-6 to - 7 diopters), and AL (about 26 mm) are exceeded. The 5-year, 6-year, and 12-year incidence of MMD is up to 1.1%, 1.2%, and 10.3% respectively. The 10-year progression rate of MMD may reach 35.5%, often involving the development or worsening of chorioretinal atrophy. MMD is associated with significant visual impairment (VI) and blindness, with a decrease in best corrected visual acuity (BCVA) ranging from one to 13 lines. Among individuals with MMD, up to 54.5% experience VI, and up to 14.9% develop blindness in the better eye. Up to 36.4%, 21.6%, 12.3%, and 4.5% of individuals with MMD have unilateral VI, bilateral VI, unilateral blindness, and bilateral blindness, respectively. BCVA loss increases with MMD severity. These findings underscore the urgent need for public health strategies to address the growing burden of MMD in Asia's aging and increasingly myopic populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.